Professor Ernst Wolvetang
|Professor Ernst Wolvetang|
BSc (Hons) U Amsterdam, PhD U Amsterdam
Telephone: +61 7 334 63894 Email: email@example.com
Research: Induced pluripotent stem cells, in vitro disease models, novel regenerative medicine approaches
Professor Ernst Wolvetang is leading the derivation of footprint-free induced pluripotent stem cells (iPSC) in Australia, with a particular focus on neuronal and cardiac disease models. He is the inaugural director of the collaborative reprogramming network Cell Reprogramming Australia and organises the only annual Australian iPSC workshop. Professor Wolvetang is a chief investigator at the Australian Research Council’s Special Research Initiative in Stem Cell Science, Stem Cells Australia and two National Health and Medical Research Council (NHMRC) project grants (2013-2015).
Professor Wolvetang has international collaborations with the University of Dammam, Saudi Arabia; Utrecht University, The Netherlands; The University of Copenhagen, Denmark; and the National University of Singapore.
Memberships, patents and funding
Professor Wolvetang serves on the editorial board of six stem cell journals; is listed inventor on four patents in stem cell research; and is the recipient of more than $2.5 million in grant funding in the past five years. He is a senior reprogramming scientist in Stem Cells Ltd, chaired the Genetic Stability of Stem Cells session at the 2007 International Society for Stem Cell Research (ISSCR) conference in Cairns and organizes, among others, the Frontiers in Reprogramming conference.
Awards and plenaries
Professor Wolvetang has given 25 lectures and was invited speaker at 23 platform meetings, including two keynote addresses. He spoke at the International Society for Stem Cell Research (ISSCR) conference in Toronto, Canada in 2006; and the 2nd Annual World Congress of Regenerative Medicine & Stem Cell in Dalian, China in 2009. Professor Wolvetang organised a master-class on iPS cells at The 2nd Annual World Stem Cells & Regenerative Medicine Congress in Seoul, Korea in 2010.
Key publications for the past five years
Wolvetang E, Herszfeld D, Langton-Bunker E, Chung T, Filipczyk A, Houssami S, Koh K, Laslett AL, Michalska A, Nguyen L, Reubinoff BE, Tellis I, Auerbach JM, Ording CJ, Looijenga LHJ, Pera MF. (2006) CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat Biotech 24(3), 351-357.
Chung T-L, Brena RM, Kolle G, Grimmond SM, Berman BP, Laird PW, Pera MF, Wolvetang EJ. (2010) Vitamin C promotes widespread yet specific demethylation of the hESC epigenome. Stem Cells 28(10), 1848-1855.
Chen YS, Pelekanos RA, Ellis RL, Horne R, Wolvetang EJ, Fisk NM. (2011) Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/ Stromal Cells. Stem cells Translational Medicine 1, 83-95.
Nayler SP, Gatei M, Kozlov S, Gatti R, Mar JC, Wells CA, Lavin M, Wolvetang EJ. (2012) Induced pluripotent stem cells from ataxia-telangiectasia recapitulate the cellular phenotype. Stem cells Translational Medicine 1, 523-535.
Briggs JA, Sun J, Shepherd J, Ovchinnikov DA, Chung TL, Nayler SP, Kao LP, Morrow CA, Thakar NY, Soo SY, Peura T, Grimmond SM, Wolvetang EJ. (2012) Integration-free iPS cells identify genetic and neural developmental features of Down syndrome etiology. Stem Cells 31(3), 467-478.
Briggs JA, Mason E, Ovchinnikov DA, Wells CA, Wolvetang EJ. (2012) New paradigms for Down syndrome research using iPSCs: tackling complex human genetic disease. Stem Cells Translational Medicine 2(3), 175-184.
|Professor Ernst Wolvetang section|